A Novel Synthetic Htert-Mini-cmv Chimera Promoter-Driven Tumor-Selective and High-Efficiency Expression of Transgene for Systemic Cancer Gene Therapy

Guanglin Wu,Wuguo Deng,Vikas Kundra,Bingliang Fang,Jack A. Roth,Lin Ji

IF: 11.2

2005-01-01

Cancer Research

Abstract:3358 One of the major obstacles to a successful cancer gene therapy is the lack of an effective systemic delivery system that can be specifically targeted to primary and metastatic tumors. The hTERT promoter has been cloned and showed to be capable of targeting transgene expression in tumors but not in the normal cells. However, the weak transcription-promoting strength of hTERT promoter, like most other intrinsic mammalian promoters, has hampered its direct use for cancer gene therapy. To circumvent these problems, we have developed a novel chimera hTERT-mini-CMV (hTMC) promoter that was engineered by optimally fusing essential hTERT regulatory sequence with minimal CMV promoter elements. We transfected various human cancers and normal cells with various EGFP-constructs, in which EGFP expression is driven by either the original CMV and hTERT promoters or by the hTMC promoter in vitro. Expression of EGFP in the transfectants was visualized by a fluorescence imaging (FI) under a fluorescence microscope and the population of EGFP-positive cells and fluorescence intensity were quantified by FACS analysis. A high level of EGFP expression driven by the hTMC promoter was detected in all tumor cells but not in normal cells. While a similar tumor-selectivity of EGFP expression driven by hTERT promoter could be seen but the level of expression was several hundred-fold lower than that driven by hTMC promoter under the same transfection efficiency. We also evaluated the effectiveness of hTMC promoter in vivo by systemic injection of DOTAP:cholesterol-complexed hTMC-EGFP-nanoparticles into nude mice that bear intrathoracic human N417 lung tumor xenografts. Consistently, a high level of EGFP expression could be detected only in the tumor cells in animals treated with hTMC-EGFP but not in any other normal tissues. Furthermore, we used the above N417 tumor mouse model to evaluate the therapeutic efficacy of systemic treatment with a novel hTMC-FUS1-nanoparticle by a non-invasive and quantitative MR imaging analysis. A significant inhibition (P